{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McAdams D"],"funding":["Bill and Melinda Gates Foundation"],"pagination":["5069-5078"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9405915"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(34)"],"pubmed_abstract":["Rotavirus infections remain a leading cause of morbidity and mortality among infants residing in low- and middle-income countries. To address the large need for protection from this vaccine-preventable disease we are developing a trivalent subunit rotavirus vaccine which is currently being evaluated in a multinational Phase 3 clinical trial for prevention of serious rotavirus gastroenteritis. Currently, there are no universally accepted in vivo or in vitro models that allow for correlation of field efficacy to an immune response against serious rotavirus gastroenteritis. As a new generation of non-replicating rotavirus vaccines are developed the lack of an established model for evaluating vaccine efficacy becomes a critical issue related to how vaccine potency and stability can be assessed"],"journal":["Vaccine"],"pubmed_title":["Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency."],"pmcid":["PMC9405915"],"funding_grant_id":["OPP1038301"],"pubmed_authors":["White JA","Estrada M","Hickey JM","Plikaytis B","Holland D","Kumar P","Volkin DB","Cryz S","Joshi SB","Sitrin R","Singh J","Sawant N","McAdams D"],"additional_accession":[]},"is_claimable":false,"name":"Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency.","description":"Rotavirus infections remain a leading cause of morbidity and mortality among infants residing in low- and middle-income countries. To address the large need for protection from this vaccine-preventable disease we are developing a trivalent subunit rotavirus vaccine which is currently being evaluated in a multinational Phase 3 clinical trial for prevention of serious rotavirus gastroenteritis. Currently, there are no universally accepted in vivo or in vitro models that allow for correlation of field efficacy to an immune response against serious rotavirus gastroenteritis. As a new generation of non-replicating rotavirus vaccines are developed the lack of an established model for evaluating vaccine efficacy becomes a critical issue related to how vaccine potency and stability can be assessed","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-06-01T01:32:27.916Z","creation":"2025-06-01T01:32:27.916Z"},"accession":"S-EPMC9405915","cross_references":{"pubmed":["35871866"],"doi":["10.1016/j.vaccine.2022.07.017"]}}